Ponatinix 15mg (Ponatinib)

Description

Ponatinix 15mg (Ponatinib)

A subset of patients with chronic myeloid leukaemia are treated with this medication. Inhibitors of multiple tyrosine kinases, a class to which it belongs, are responsible for its effects. When used to treat chronic myeloid leukaemia, it is highly effective when the disease has the T315I mutation. Ponatinib is the name under which this drug is marketed in the generic market. This pharmaceutical product is made and sold by Beacon Pharmaceuticals, LTD.

Dosage 

This medicine is recommended orally once daily upon achievement of ≤1% BCR-ABL 1 IS. You can take Ponatinix 15mg with or without food. 

Side Effects 

• inflammation of the pancreas
• Bladder pain
• increased risk of stroke.
• dizziness
• heart problems.
• Fainting

Storage 

A storage range of 20–25 degrees Celsius (68–77 degrees Fahrenheit) is recommended, with 15–30 degrees Celsius (59–86 degrees Fahrenheit) as an absolute maximum. Do not expose this to any moisture or sunlight.